Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;19(9):2314-2317.
doi: 10.1111/jth.15420. Epub 2021 Jul 7.

Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine

Hannah Maayan  1 , Ilya Kirgner  2   3 , Odit Gutwein  1 , Katrin Herzog-Tzarfati  1 , Naomi Rahimi-Levene  1   3   4 , Maya Koren-Michowitz  1   3 , Dorit Blickstein  1
Affiliations

Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine

Hannah Maayan et al. J Thromb Haemost. 2021 Sep.

Abstract

Background: In December 2020 the Israeli Health Ministry began a mass vaccination campaign with the BNT162b2 vaccine. This was an important step in overcoming the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) pandemic. Autoimmune phenomenon have been described after receiving vaccinations.

Patients/methods: Here we describe a case series of patients who developed acquired Thrombotic Thrombocytopenic Purpura, a rare autoimmune disease, within several days of receiving the BNT162b2 vaccine.

Conclusions: A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity should be evaluated in patients with history of aTTP before and after any vaccination, especially the SARS-CoV-2 vaccination, and immunosuppression treatment should be considered before vaccination in cases of low ADAMTS13 activity. Patients should be closely monitored after the vaccine for clinical situation and laboratory data. Post vaccination thrombocytopenia assessment should include immune thrombocytopenic purpura, vaccine-induced immune thrombotic thrombocytopenia and acquired thrombotic thrombocytopenic purpura.

Keywords: ADAMTS-13; BNT162b2 vaccine; SARS-CoV-2; acquired thrombotic thrombocytopenic purpura; autoimmunity.

PubMed Disclaimer

Comment in

References

    1. Polack F.P., Thomas S.J., Kitchin N., et al. Safety and efficacy of the BNT162b2 mRNA Covid‐19 vaccine. N Engl J Med. 2020;383(27):2603–2615. - PMC - PubMed
    1. Dagan N., Barda N., Kepten E., et al. BNT162b2 mRNA Covid‐19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384:1412–1423. - PMC - PubMed
    1. Scully M., Hunt B.J., Benjamin S., et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3):323–335. - PubMed
    1. Albiol N., Awol R., Martino R. Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID‐19. Ann Hematol. 2020;99(7):1673–1674. - PMC - PubMed
    1. Li A., Khalighi P.R., Wu Q., Garcia D.A. External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment. J Thromb Haemost. 2018;16(1):164–169. - PMC - PubMed

MeSH terms